N.C. pharma Pozen wins injunction blocking generic migraine drug
Generic competition to Pozen’s (NASDAQ:POZN) migraine drug Treximet will be held at bay for now. A judge in the U.S. District Court for the Eastern District of Texas has granted a preliminary injunction that orders Par Pharmaceutical (NYSE:PRX) not to make or sell a generic version of Treximet, which is sold in the United States […]